---
figid: PMC7559774__40364_2020_233_Fig3_HTML
figtitle: tRF-Leu-CAG, ts-101, ts-46, and ts-47 are involved in drug resistance of
  lung cancer cells
organisms:
- Homo sapiens
- Mus musculus
- transposons
pmcid: PMC7559774
filename: 40364_2020_233_Fig3_HTML.jpg
figlink: pmc/articles/PMC7559774/figure/Fig3/
number: F3
caption: tRF-Leu-CAG, ts-101, ts-46, and ts-47 are involved in drug resistance of
  lung cancer cells. Knockdown of tRF-Leu-CAG downregulates AURKA. AURKA overexpression
  induces gefitinib resistance by downregulating p53. The AURKA/NF-ĸB pathway is related
  to radio-resistance. ts-46 is associated with excessive activation of ILK, integrin,
  and mTOR signaling. Both ts-46 and ts-101 are correlated with the inhibition of
  PTEN signaling. RNA silencing of ILK enhances cisplatin sensitivity by regulating
  p-GSK3β, p-AKT, AP-1, β-catenin, cyclin D1, and MMP-9. Integrin activates Akt, which
  determines resistance to cisplatin. Integrin mediates EGFR-TKIs resistance through
  EMT, the KRAS-RalB-NF-κB pathway, and the Src/Akt pathway. Integrin/Src/Akt in NSCLC
  cells confers resistance to cixutumumab. PI3K/AKT/mTOR signaling promotes chemoresistance.
  ts-46 and ts-47 can affect the p53 pathway, which mediates cisplatin resistance
  in NSCLC
papertitle: Mechanisms of tRNA-derived fragments and tRNA halves in cancer treatment
  resistance.
reftext: Yue Zhang, et al. Biomark Res. 2020;8:52.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9695467
figid_alias: PMC7559774__F3
figtype: Figure
organisms_ner:
- Mus musculus
- Homo sapiens
redirect_from: /figures/PMC7559774__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7559774__40364_2020_233_Fig3_HTML.html
  '@type': Dataset
  description: tRF-Leu-CAG, ts-101, ts-46, and ts-47 are involved in drug resistance
    of lung cancer cells. Knockdown of tRF-Leu-CAG downregulates AURKA. AURKA overexpression
    induces gefitinib resistance by downregulating p53. The AURKA/NF-ĸB pathway is
    related to radio-resistance. ts-46 is associated with excessive activation of
    ILK, integrin, and mTOR signaling. Both ts-46 and ts-101 are correlated with the
    inhibition of PTEN signaling. RNA silencing of ILK enhances cisplatin sensitivity
    by regulating p-GSK3β, p-AKT, AP-1, β-catenin, cyclin D1, and MMP-9. Integrin
    activates Akt, which determines resistance to cisplatin. Integrin mediates EGFR-TKIs
    resistance through EMT, the KRAS-RalB-NF-κB pathway, and the Src/Akt pathway.
    Integrin/Src/Akt in NSCLC cells confers resistance to cixutumumab. PI3K/AKT/mTOR
    signaling promotes chemoresistance. ts-46 and ts-47 can affect the p53 pathway,
    which mediates cisplatin resistance in NSCLC
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Pten
  - Aurka
  - Ilk
  - Trp53
  - Kras
  - Src
  - Ptk2
  - Itk
  - Slc22a3
  - Pik3r1
  - Nfkb1
  - Gsk3b
  - Jun
  - Ccnd1
  - Akt1
  - Ralb
  - Abcc1
  - Prl2c2
  - Ccl6
  - Mmp9
  - Mtor
  - PTEN
  - AURKA
  - ILK
  - TP53
  - TP63
  - TP73
  - KRAS
  - NRAS
  - SRC
  - FGR
  - FYN
  - YES1
  - PTK2
  - ITK
  - SLC22A3
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - NFKB1
  - GSK3B
  - FOS
  - FOSB
  - JUN
  - JUNB
  - JUND
  - CCND1
  - AKT1
  - AKT2
  - AKT3
  - RALB
  - CD9
  - MDM4
  - ABCC1
  - MSH3
  - MMP9
  - MTOR
  - Leu
  - cisplatin
  - Gemcitabine
  - paclitaxel
---
